Mepolizumab, targeting interleukin-5 (IL-5), has been evaluated in eosinophilic granulomatosis with polyangiitis (EGPA), a subset of AAV. This evidence concerns the gene IL5 and eosinophilic granulomatosis with polyangiitis.